At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
LMN-201 Anti-toxin B VHH-1 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies
In Brief
A Phase 1 clinical trial evaluating LMN-201 Anti-toxin B VHH-1, LMN-201 Anti-toxin B VHH-2, and 2 other interventions for C. Diff. Infections. Completed, enrolled 12 participants across 3 sites.
Detailed Summary
This is a Phase 1, single-site, open label, exploratory study to assess delivery of LMN-201 components via enteric capsules in the gut of individuals with ostomies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsC. Diff. Infections
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartAug 2021
Primary CompletionFeb 2022
TodayJul 2026
First PostedMay 19, 2021
Enrollment StartAug 18, 2021
Primary CompletionFeb 23, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.1 years ago
Interventions
LMN-201 Anti-toxin B VHH-1biological
Components of LMN-201
LMN-201 Anti-toxin B VHH-2biological
Components of LMN-201
LMN-201 Anti-toxin B VHH-3biological
Components of LMN-201
LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3biological
Components of LMN-201